OncLive TV

Sara M. Tolaney, MD, MPH, discusses the phase 2 APT and ATEMPT trials in stage I HER2-positive breast cancer.

Aman Chauhan, MD, a medical oncologist at the University of Kentucky, discusses key recent advances in therapeutics for patients with neuroendocrine tumors, and points to the future with ongoing combination studies.

Jonathan Strosberg, MD, discusse​s retreatment with Lutathera in advanced neuroendocrine tumors.

Aman Chauhan, MD, a medical oncologist at the University of Kentucky, discusses the role of ​Lutathera in neuroendocrine tumors.

Seema A. Bhat, MD, hematologist, discusses the role of targeted therapies in chronic lymphocytic leukemia.

Alex Duval, MD, PhD, discusses the use of microsatellite instability–high as a biomarker of response to therapy in patients with cancer.

David Gerber, MD, discusses the rationale to combine immunotherapy with radiation therapy in lung cancer.

Rebecca Silbermann, MD, MMS, discusses current treatment options for fit patients with multiple myeloma who experience early relapse.

John A. Abraham, MD, FACS, discusses the surgical management of patients with tenosynovial giant cell tumor.

Marianne Pavel, MD, discusses the progression-free survival of patients with pancreatic and midgut neuroendocrine tumors who are treated with lanreotide autogel in the phase 2 CLARINET FORTE trial.

Edward Wolin, MD, discusses the safety profile of 177Lu-dotatate in patients with advanced neuroendocrine tumors.

Sara M. Tolaney, MD, MPH, discusses the evolution of treatment in HER2-positive breast cancer.

Erika P. Hamilton, MD, highlights initial findings from the ​ongoing phase 1b/2 LIO-1 trial in advanced metastatic tumors.

John Zalcberg, ​PhD, OAM, discusses the management of patients with gastrointestinal stromal tumor​.

Edward Chu, MD, MMS, discusses the role of pembrolizumab in patients with mismatch repair deficient or microsatellite instability–high metastatic colorectal cancer.

Sumanta K. Pal, MD, discusses the safety profile of cabozantinib in combination with atezolizumab in advanced renal cell carcinoma.

Giuseppe Giaccone, MD, PhD, discusses current treatment options in non–small cell lung cancer.

Andre Goy, MD, MS, discusses the utility of next-generation sequencing in identifying aggressive subtypes of mantle cell lymphoma.

Philip W. Kantoff, MD, discusses current approaches for patients with metastatic hormone-sensitive prostate cancer, and nonmetastatic/metastatic castration-resistant prostate cancer who progress on androgen blocking agents.

Christine Sam, MD, discusses the importance of ​performing geriatric assessments during the coronavirus disease 2019 pandemic​.

Andrew B. Nixon, PhD, ​MBA, discusses the role of immunohistochemistry and multiplex polymerase chain reactions tests in detecting microsatellite instability–high tumors.

Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, discusses the importance of patient-reported outcomes in the phase 1 GARNET trial in advanced or recurrent mismatch repair deficient/microsatelite instability-high endometrial cancer.

Martin Reck, MD, PhD, discusses the safety profile observed with of pembrolizumab versus chemotherapy in patients with metastatic non–small cell lung cancer in the phase 3 KEYNOTE-024 trial.

Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the rationale for the addition of darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk prostate cancer.

Isabella C. Glitza Oliva, MD, PhD, MS, discusses ​the potential utility of pembrolizumab in combination with selinexor in advanced melanoma.

Alexander M. M. Eggermont, MD, PhD, discusses the rationale for the phase 3 EORTC 1325/KEYNOTE-054 trial, ​evaluating adjuvant pembrolizumab versus placebo, in advanced melanoma.

Manish A. Shah, MD, discusses the rationale for the phase 3 KEYNOTE-590 trial in ​locally advanced or metastatic esophageal carcinoma.

Paul L. Nguyen, MD, discusses treatment considerations in high-risk prostate cancer.

Atish D. Choudhury, MD, PhD, discusses the design of key clinical trials in nonmetastatic castration-resistant prostate cancer.

Maha Hussain, MD, FACP, FASCO, discusses the rationale for targeting the DNA repair pathway in metastatic castration-resistant prostate cancer.